Such a mechanism ensures the maintenance of the EGFR/CDK2 signaling axis, which promotes tumor cell proliferation and provides IDH-wt GBM tumor cells with an additional layer of resistance against targeted EGFR/CDK2 inhibition. The gene discussed is EGFR; the disease is glioblastoma.